Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review

Camillo Porta, Cezary Szczylik, Bernard Escudier

Research output: Contribution to journalArticle

Abstract

The introduction of novel anti-angiogenic therapies has greatly improved the outcome of patients with metastatic renal cell carcinoma (mRCC). The use of these therapies in combination or sequentially is proposed to provide greater efficacy.We have reviewed completed and ongoing clinical trials in mRCC that have reported efficacy and/or safety data of novel therapies used in combination or sequentially.Bevacizumab appears to be a useful partner when combined with interferon (IFN), while controversial results have been reported when combined with temsirolimus and everolimus. Other combinations appear to have unacceptable tolerability or require dose or schedule optimization. Sequencing data provide a clear indication that multiple lines of treatment may extend survival. The 'ideal' sequence, however, is still unknown.In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy.

Original languageEnglish
Pages (from-to)323-337
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume82
Issue number3
DOIs
Publication statusPublished - Jun 2012

Keywords

  • Angiogenesis inhibitors
  • Combination
  • Cytokines
  • Renal cell carcinoma
  • Sequencing

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review'. Together they form a unique fingerprint.

  • Cite this